Compare · AAPG vs NVO
AAPG vs NVO
Side-by-side comparison of Ascentage Pharma Group International (AAPG) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AAPG and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $183.15B, about 114.6x AAPG ($1.60B).
- Over the past year, AAPG is down 29.8% and NVO is down 45.7% - AAPG leads by 15.9 points.
- AAPG has been more active in the news (10 items in the past 4 weeks vs 8 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 8 for AAPG).
- Company
- Ascentage Pharma Group International
- Novo Nordisk A/S
- Price
- $19.35-2.62%
- $41.01-4.51%
- Market cap
- $1.60B
- $183.15B
- 1M return
- -17.20%
- -10.44%
- 1Y return
- -29.79%
- -45.66%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2025
- News (4w)
- 10
- 8
- Recent ratings
- 8
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest AAPG
- SEC Form 6-K filed by Ascentage Pharma Group International
- Ascentage Pharma Presents Data on Olverembatinib in CML-LBP and Ph+ BCP-ALL at ASCO 2026
- Ascentage Pharma Presents Its First Dataset on MDM2-p53 Inhibitor Alrizomadlin (APG-115) in Pediatric Solid Tumors at ASCO 2026
- Ascentage Pharma Presents Updated Clinical Data for Olverembatinib as Second-Line Therapy in CML-CP at ASCO 2026
- SEC Form 6-K filed by Ascentage Pharma Group International
- SEC Form 6-K filed by Ascentage Pharma Group International
- Chief Medical Officer Zhai Yifan converted options into 188,321 units of Ordinary Shares, increasing direct ownership by 30% to 405,280 units (SEC Form 4)
- Chairman and CEO Yang Dajun converted options into 188,321 units of Ordinary Shares, increasing direct ownership by 9% to 1,193,569 units (SEC Form 4)
- SEC Form 6-K filed by Ascentage Pharma Group International
- Ascentage Pharma Releases Latest Clinical Data from Multiple Trials at ASCO 2026
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care